

Varian Halcyon™ Commissioned at MedStar Southern Maryland Hospital Center Using myQA® HALO Solution from IBA Dosimetry


myQA HALO beam data collection and independent commissioning solution enables the Radiation Oncology Center at MedStar Southern Maryland Hospital Center fast clinical implementation of a Varian Halcyon™

Baltimore, MD, USA, April 2nd, 2019 – IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces the successful commissioning of the Varian Halcyon™ at the Radiation Oncology Center at MedStar Southern Maryland Hospital Center, based on IBA Dosimetry independent beam scanning solution.

IBA has designed *myQA HALO*, a dedicated solution that allows medical physicists to efficiently and accurately perform all the required scanning for commissioning, acceptance and annual testing of the Halcyon system. The team at MedStar Health has now successfully commissioned their new Halcyon Machine version 2.0 using the *myQA HALO* solution. The entire commissioning work including system setup and all measurements was completed efficiently in one day as confirmation of the Gold Standard data used in the RTPS.



myQA HALO system setup at MedStar Southern Maryland Hospital Center for commissioning of the Halcyon system.



A smooth Halcyon 2 x 2 cm 2 beam profile, measured by the MedStar Southern Maryland Hospital Center team using $myQA\ HALO$.

Press release | 02/04/2019

IBA | Dosimetry GmbH



1

Press Release



"We are excited about the fast adoption of IBA Dosimetry's dedicated solutions for Integrated Quality Assurance for the Varian Halcyon™ system," said **Jean-Marc Bothy, President of IBA Dosimetry GmbH.** "We are proud that the team at MedStar has chosen the myQA HALO for the commissioning and upcoming QA work."

The myQA HALO system

The $myQA\ HALO$ system is specifically designed to enable independent commissioning and efficient beam data collection for the Varian HalcyonTM system.

The system consists of leading-edge Beam Scanning components that are proven, clinically implemented, and trusted by over 4,000 satisfied users worldwide!

Key components include the Blue Phantom Compact, a small footprint, lightweight water phantom that addresses weight requirements of the Varian Halcyon™ couch.

The Stealth Reference Chamber, with its dedicated Halcyon holder, supports small field beam scanning accuracy and excellent reproducibility of field sizes down to 0.5 x 0.5 cm².

The *myQA Accept* scanning software, the most widely used solution worldwide, enables beam scanning efficiency that is integrated into the myQA® global software platform.

To find out more please visit iba-dosimetry.com

ends

About IBA Dosimetry

IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.

Find more information at iba-dosimetry.com

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

Press release | 02/04/2019



2

Press Release



IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at iba-worldwide.com

Media Contact:

Ralf Schira, Director Global Marketing, IBA Dosimetry, ralf.schira@iba-group.com